Article Figures & Data
Figures
- FIGURE 1.
Schema of clinical disease state model of prostate cancer before VISION. (Adapted from (33).)
- FIGURE 2.
Protocol schema for VISION trial. ECOG = Eastern Cooperative Oncology Group; LDH = lactate dehydrogenase.
Tables
- TABLE 1.
Anticancer Therapeutic Radiopharmaceuticals Currently Approved by Regulators in United States
Agent Trade name Year of FDA approval Primary endpoint Indication 89Sr-chloride Metastron (GE Healthcare) 1993 Pain/analgesics Painful skeletal metastases 153Sm-lexidronam Quadramet (Dow Chemical Co.) 1997 Pain/analgesics Painful osteoblastic metastases 90Y-ibritumomab tiuxetan Zevalin (Acrotech Biopharma) 2002 Tumor response rate Low-grade or follicular lymphoma 131I-tositumomab Bexxar (GlaxoSmithKline) 2003 Tumor response rate Low-grade or follicular lymphoma 223Ra-dichloride Xofigo (Bayer) 2013 OS mCRPC 177Lu-DOTATATE Lutathera (Advanced Accelerator Applications) 2018 Progression-free survival Select neuroendocrine tumors 131I-iobenguane Azedra (Progenics Pharmaceuticals) 2018 Lower blood pressure and tumor response rate Select pheochromocytoma or paraganglioma 177Lu-PSMA-617 Pluvictoa (Advanced Accelerator Applications) 2022 OS and rPFS PSMA PET-positive mCRPC after ARPI and taxane PSMA = prostate-specific membrane antigen.
Trial Front-line mCRPC TAX 327 Docetaxel/prednisone vs. mitoxantrone/prednisone (10) SWOG 9916 Docetaxel plus estramustine vs. mitoxantrone/prednisone (11) IMPACT Sipuleucel-T vs. nonactivated immune cell control (19) COU-AA-302 Abiraterone/prednisone vs. placebo/prednisone (13) ALSYMPCA SOC ± 223Ra (18) PREVAIL Enzalutamide vs. placebo (15) After docetaxel TROPIC Cabazitaxel/prednisone vs. mitoxantrone/prednisone (16) COU-AA- 301 Abiraterone/prednisone vs. placebo/prednisone (12) AFFIRM Enzalutamide vs. placebo (14) ALSYMPCA SOC ± 223Ra (18) After ARPI or ARPI plus docetaxel in HRR mutated subset only PROfound Olaparib vs. abiraterone or enzalutamide (20) After ARPI and DOCETAXEL) CARD Cabazitaxel vs. abiraterone or enzalutamide (17) VISION SOC ± PSMA-617 177Lu HRR = homologous recombination repair.
